Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — A small group of physicians with deep, at times undisclosed, financial ties to the drug maker Biogen has emerged as the most vocal defenders of the company’s questionably effective and costly Alzheimer’s drug, Aduhelm.

The four doctors, who all served as consultants to Biogen in 2020, have written articles in scientific journals defending the drug, praised the drug in the press, and appealed directly to the Food and Drug Administration to approve the drug — sometimes without disclosing that they had served as paid consultants for the company. Since 2014, the four have taken in $117,000 in consulting fees from the company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment